Table 4 Distribution of births across delivery settings and coverage of uterotonics at each delivery setting in status quo and intervention scenarios. Values modelled in sensitivity analysis are indicated in parentheses
| Â | Setting 1 | Setting 2 | Setting 3 | Setting 4 | Setting 5 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Value | Source | Value | Source | Value | Source | Value | Source | Value | Source | |
Bangladesh | ||||||||||
Births taking place at setting | 4.0% | BMMS 2016 [13] | 9.3% | BMMS 2016 [13] | 3.7% | BMMS 2016 [13] | 50.2% | BMMS 2016 [13] | 32.8% | BMMS 2016 [13] |
Births receiving each uterotonic in status quo | ||||||||||
  Injectable oxytocin | 90.2% | Health facility survey [15] | 83.9% | Health facility survey [15] | 11% | Health facility survey [15] | 0% | Assumption | 86% | Health facility survey [15] |
  Misoprostol | 0% | Assumption | 0% | Assumption | 69% | 42%b | Quaiyum et al. 2014 [41] | 0% | Assumption | |
Births receiving each uterotonic in intervention scenarioa | ||||||||||
  Injectable oxytocin | 63% | BMMS 2016 [13] | 20% | BMMS 2016 [13] | 0% | Assumption | 0% | Assumption | 86% | BMMS 2016 [13] |
  Misoprostol | 0% | Assumption | 0% | Assumption | 0% | Assumption | 0% | Assumption | 0% | Assumption |
  Inhaled oxytocin | 28% | Assumption | 64% | Assumption | 80% | Assumption | 42% b | Assumption | 0% | Assumption |
Ethiopia | ||||||||||
Births taking place at setting | 9.5% | EmONC assessment 2016 [17] | 58.4% | EmONC assessment 2016 [17] | 4.5% | Sibley et al. 2014 [18] | 25.5% | Sibley et al. 2014 [18] | 2.1% | EmONC assessment 2016 [17] |
Births receiving each uterotonic in status quo | ||||||||||
  Injectable oxytocin | 81% | EmONC assessment 2016 [17] | 81% | EmONC assessment 2016 [17] | 0% | Assumption | 0% | Assumption | 81% | EmONC assessment 2016 [17] |
  Misoprostol | 0% | Assumption | 0% | Assumption | 84%c | Health facility survey [42] | 0% | Assumption | 0% | Assumption |
Births receiving each uterotonic in intervention scenarioa | ||||||||||
  Injectable oxytocin | 2% | EmONC assessment 2016 [17] | 0% | Assumption | 0% | Assumption | 0% | Assumption | 81% | EmONC assessment 2016 [17] |
  Misoprostol | 0% | Assumption | 0% | Assumption | 0% | Assumption | 0% | Assumption | 0% | Assumption |
  Inhaled oxytocin | 78% | Assumption | 81% | Assumption | 84% c | Assumption | 0% | Assumption | 0% | Assumption |